XMS Stock Overview Provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Xtant Medical Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Xtant Medical Holdings Historical stock prices Current Share Price US$0.44 52 Week High US$1.15 52 Week Low US$0.33 Beta 0.32 1 Month Change 20.33% 3 Month Change -17.36% 1 Year Change -61.91% 3 Year Change -14.95% 5 Year Change -69.58% Change since IPO -83.66%
Recent News & Updates
Third quarter 2024 earnings released: US$0.037 loss per share (vs US$0.072 profit in 3Q 2023) Nov 15
Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 14
Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
New minor risk - Profitability Oct 18
Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System Sep 24
Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus Sep 18 See more updates
Third quarter 2024 earnings released: US$0.037 loss per share (vs US$0.072 profit in 3Q 2023) Nov 15
Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 14
Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
New minor risk - Profitability Oct 18
Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System Sep 24
Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus Sep 18
New major risk - Share price stability Sep 05 Xtant Medical Holdings, Inc. announced that it has received $5 million in funding Aug 13
New minor risk - Shareholder dilution Aug 11
Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2023) Aug 09
Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024 Aug 09 Xtant Medical Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024 Jun 13
New minor risk - Profitability Jun 07
New minor risk - Financial position May 17
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024 May 17
Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds May 01
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds Apr 30
Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Apr 03
Full year 2023 earnings released: EPS: US$0.006 (vs US$0.09 loss in FY 2022) Apr 02
Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024 Mar 22
Investor sentiment improves as stock rises 23% Feb 29
Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023 Nov 10
Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.025 loss in 3Q 2022) Nov 10
Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023 Aug 03
Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.02 loss in 2Q 2022) Aug 02
Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 26 Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding Jul 04
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Jun 21
Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors May 19
First quarter 2023 earnings released: US$0.019 loss per share (vs US$0.025 loss in 1Q 2022) May 07
Xtant Medical Holdings, Inc. Announces Executive Changes May 06
Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023 May 05
Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021) Mar 09
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023 Feb 02
Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023 Jan 10
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021) Nov 04
Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022 Sep 01 Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding
Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021) Aug 05
Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
First quarter 2022 earnings released: US$0.025 loss per share (vs US$0 in 1Q 2021) May 06
Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022 May 03
Less than half of directors are independent Apr 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 09
Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Mar 03
Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020) Nov 13
Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020) Aug 09
Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding Feb 26
Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019) Feb 25
Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding Feb 24
Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €1.49 Feb 11
New 90-day high: €1.20 Jan 24
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue misses expectations Oct 30
Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards Oct 07 Xtant Medical Holdings, Inc. announced that it expects to receive $62.882 million in funding
New 90-day low: €0.65 Sep 28
New 90-day low - €0.66 Sep 11
New 90-day low - €0.76 Aug 21
First half earnings released Aug 04
Xtant Medical Holdings, Inc. to Report Q2, 2020 Results on Aug 03, 2020 Jul 31
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Growth Index Jul 05
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Index Jul 02 Shareholder Returns XMS DE Medical Equipment DE Market 7D 6.8% -1.7% -0.4% 1Y -61.9% -6.8% 7.9%
See full shareholder returns
Return vs Market: XMS underperformed the German Market which returned 7.9% over the past year.
Price Volatility Is XMS's price volatile compared to industry and market? XMS volatility XMS Average Weekly Movement 11.6% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: XMS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XMS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.
Show more Xtant Medical Holdings, Inc. Fundamentals Summary How do Xtant Medical Holdings's earnings and revenue compare to its market cap? XMS fundamental statistics Market cap €71.09m Earnings (TTM ) -€17.07m Revenue (TTM ) €110.49m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) XMS income statement (TTM ) Revenue US$113.86m Cost of Revenue US$44.53m Gross Profit US$69.33m Other Expenses US$86.92m Earnings -US$17.59m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.13 Gross Margin 60.89% Net Profit Margin -15.45% Debt/Equity Ratio 76.1%
How did XMS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 11:51 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Xtant Medical Holdings, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Wittes Aegis Capital Corporation Jason Wittes Brean Capital Michael Gorman BTIG
Show 10 more analysts 
